Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, FDA

Zetta's advanced MRI software engine, ZOOMtm receives FDA 510(k) clearance


LAKE ZURICH, Ill., June 25, 2018 /PRNewswire/ -- Zetta Medical Technologies announces their new FDA cleared software ZOOMtm.

ZOOM: Enable Short Scanning

Zetta Medical Technologies announces the release of its latest MRI software algorithm for image quality enhancement and image optimization of short scanning techniques.

ZOOMtm is vendor neutral that works with all MRI models from all major manufacturers. Its core algorithm was designed to help MRI imaging departments to automatically process all MRI imaging techniques, including time sensitive short scans.

ZOOMtm utilizes standard DICOM communications protocol to receive data, processes it and automatically transfers the enhanced images to PACS. Its powerful engine can simultaneously manage incoming data from multiple scanners to satisfy aggressive workflow demands. Developed in the USA by Zetta, ZOOMtm helps MRI imaging departments maintain patient care, increase patient throughput and improve scanning profitability.

ZOOMtm joins Zetta's suite of innovative software solutions (ZIAtm, Z-DOSE29tm, ZDOSE-RPtm, Z-LINKtm and Z-PULSEtm) designed and developed with hospitals and imaging centers in mind.

About Zetta Medical Technologies
Zetta Medical Technologies is a leading national independent service organization and developer of innovative software products while offering quality service solutions for CT, MRI and PET/CT equipment. What makes Zetta a leader is a wider range of service and software solutions developed for GE, Siemens, Toshiba and Philips medical equipment. Zetta is an ISO 13485:2016 certified company. For more information, contact Zetta at (847) 550-9990 or via www.ZettaMed.com

Media Contact
Mike Ghazal, President
For: Marketing & Business Process
Telephone: 847-550-9990
[email protected]

 

SOURCE Zetta Medical Technologies


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: